Biography: Life Sciences

Kim Egan is co-chair of DLA Piper's healthcare sector and is based in the Washington, DC office. She focuses on pharmaceutical, biologics, and medical device litigation and advice.

Ms Egan's work on behalf of pharmaceutical and biotechnology clients covers all aspects of a pharmaceutical product's lifecycle around the world. Her experience includes preclinical and clinical trial development, clinical data review, data safety monitoring board and adjudication board issues, FDA and EMA approval of new molecular entities or line extensions, drug labelling issues, post-marketing surveillance, promotional issues, HIPAA and other patient privacy issues, data disclosure obligations, study subject compensation issues, informed consent and payment to physician regulations, advisory committee and oral explanation preparations and WHO policies. She provides strategic advice to pharmaceutical companies on compliance with Good Clinical Practices and ICH guidelines and media strategy as well as R&D matters generally. Ms Egan also handles complex litigation issues for pharmaceutical companies, with a particular focus on scientific and regulatory fact development and witness preparation.

Ms Egan's litigation matters have included a wide variety of complex commercial litigation, such as mass tort and product liability matters in the food, pharmaceutical, asbestos, silica and medical device industries. Ms Egan has been part of the national counsel team on two major pharmaceutical MDLs in the last four years, and has also handled pharmaceutical litigation related to licensing agreements and clinical trial claims.